188 related articles for article (PubMed ID: 34146403)
1. Childhood ovarian nonseminomatous germ cell tumors: A highly curable disease with few long-term treatment-related toxicities-Results of the French TGM95 study.
Pavone R; Pacquement H; Pasquet M; Sudour-Bonnange H; Hameury F; Sarnacki S; Chastagner P; Faure-Conter C; Poirée M; Taque S; Patte C; Fresneau B
Int J Cancer; 2021 Nov; 149(9):1705-1712. PubMed ID: 34146403
[TBL] [Abstract][Full Text] [Related]
2. Is alpha-fetoprotein decline a prognostic factor of childhood non-seminomatous germ cell tumours? Results of the French TGM95 study.
Fresneau B; Orbach D; Faure-Conter C; Sudour-Bonnange H; Vérité C; Gandemer V; Pasquet M; Fasola S; Rome A; Raimbault S; Martelli H; Frappaz D; Le Teuff G; Patte C
Eur J Cancer; 2018 May; 95():11-19. PubMed ID: 29604495
[TBL] [Abstract][Full Text] [Related]
3. Extracranial germ cell tumours in children and adolescents: Results from the French TGM13 protocol.
Faure-Conter C; Orbach D; Sudour-Bonnange H; Verité C; Mansuy L; Rome A; Dumesnil C; Thebaud E; Renard M; Hameury F; Flechon A; Blanc E; Dijoud F; Fresneau B; Chabaud S
Pediatr Blood Cancer; 2023 Mar; 70(3):e30117. PubMed ID: 36451268
[TBL] [Abstract][Full Text] [Related]
4. Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study.
Terenziani M; Bisogno G; Boldrini R; Cecchetto G; Conte M; Boschetti L; De Pasquale MD; Biasoni D; Inserra A; Siracusa F; Basso ME; De Leonardis F; Di Pinto D; Barretta F; Spreafico F; D'Angelo P
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449306
[TBL] [Abstract][Full Text] [Related]
5. Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies.
Mann JR; Pearson D; Barrett A; Raafat F; Barnes JM; Wallendszus KR
Cancer; 1989 May; 63(9):1657-67. PubMed ID: 2467734
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: Experience from a tertiary cancer center.
Ramanathan S; Prasad M; Vora T; Badira CP; Kembhavi S; Ramadwar M; Khanna N; Laskar S; Muckaden MA; Qureshi S; Banavali S; Chinnaswamy G
Pediatr Blood Cancer; 2023 Apr; 70(4):e30179. PubMed ID: 36645132
[TBL] [Abstract][Full Text] [Related]
7. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
Mann JR; Raafat F; Robinson K; Imeson J; Gornall P; Sokal M; Gray E; McKeever P; Hale J; Bailey S; Oakhill A
J Clin Oncol; 2000 Nov; 18(22):3809-18. PubMed ID: 11078494
[TBL] [Abstract][Full Text] [Related]
8. Pure pediatric ovarian immature teratomas: The French experience.
Pavone R; Dijoud F; Galmiche L; Ro V; Hameury F; Sarnacki S; Orbach D; Briandet C; Pasquet M; Bertrand A; Fresneau B; Faure-Conter C
Pediatr Blood Cancer; 2020 Apr; 67(4):e28186. PubMed ID: 31981415
[TBL] [Abstract][Full Text] [Related]
9. Results from the UK Children's Cancer and Leukaemia Group study of extracranial germ cell tumours in children and adolescents (GCIII).
Depani S; Stoneham S; Krailo M; Xia C; Nicholson J
Eur J Cancer; 2019 Sep; 118():49-57. PubMed ID: 31306943
[TBL] [Abstract][Full Text] [Related]
10. Malignant extra-cranial germ cell tumors in children and adolescents. Results following the guidelines of SFOP/SFCE 95 Protocol.
Zubizarreta P; Rossa A; Bailez M; Gil S; Rose A; Cacciavillano W
Medicina (B Aires); 2016; 76(5):265-272. PubMed ID: 27723613
[TBL] [Abstract][Full Text] [Related]
11. Lowered Cisplatin Dose and No Bleomycin in the Treatment of Pediatric Germ Cell Tumors: Results of the GCT-99 Protocol From the Brazilian Germ Cell Pediatric Oncology Cooperative Group.
Lopes LF; Macedo CR; Aguiar Sdos S; Barreto JH; Martins GE; Sonaglio V; Milone M; Lima ER; Almeida MT; Lopes PM; Watanabe FM; D'Andrea ML; Pianovski MA; Melaragno R; Vianna SM; Moreira ME; Bruniera P; de Oliveira CZ
J Clin Oncol; 2016 Feb; 34(6):603-10. PubMed ID: 26729441
[TBL] [Abstract][Full Text] [Related]
12. Outcome and late effects of patients treated for childhood vaginal malignant germ cell tumors.
Coppin R; Martelli H; Chargari C; Sudour-Bonnange H; Orbach D; Vérité C; Pasquet M; Saumet L; Piguet C; Patte C; Guérin F; Faure-Conter C; Fresneau B
Pediatr Blood Cancer; 2023 Dec; 70(12):e30697. PubMed ID: 37798818
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and prognostic variables of extracranial germ cell tumors in children and adolescents treated over a decade: A developing world perspective.
Ramanathan S; Prasad M; Vora T; Parambil BC; Kembhavi S; Ramadwar M; Khanna N; Laskar S; Kurkure P; Qureshi S; Banavali S; Chinnaswamy G
Pediatr Blood Cancer; 2022 Jul; 69(7):e29765. PubMed ID: 35561025
[TBL] [Abstract][Full Text] [Related]
14. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).
Daugaard G; Skoneczna I; Aass N; De Wit R; De Santis M; Dumez H; Marreaud S; Collette L; Lluch JRG; Bokemeyer C; Schmoll HJ
Ann Oncol; 2011 May; 22(5):1054-1061. PubMed ID: 21059637
[TBL] [Abstract][Full Text] [Related]
17. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.
Tryakin A; Fedyanin M; Bulanov A; Kashia S; Kurmukov I; Matveev V; Fainstein I; Gordeeva O; Zakharova T; Tjulandin S
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1817-1823. PubMed ID: 29974210
[TBL] [Abstract][Full Text] [Related]
18. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].
Göbel U; Calaminus G; Teske C; Bamberg M; Bökkerink JP; Haas RJ; Holschneider AM; Janka-Schaub G; Jürgens H; Mittler U
Klin Padiatr; 1993; 205(4):231-40. PubMed ID: 7690864
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
20. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
Price P; Hogan SJ; Bliss JM; Horwich A
Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
